Interferon-Combination Strategies for the Treatment of Chronic Hepatitis C

 

 Permissions and Reprints

Abstract

Direct acting antiviral agents have revolutionized hepatitis C (HCV) therapy. Many agents that are either currently available or undergoing investigation offer higher rates of sustained virologic response, reduced toxicity and shorter duration of therapy when compared to traditional treatment consisting of pegylated interferon and ribavirin. Although interferon free therapy may be a preferred option, some patients may still require an interferon based regimen to ensure efficacy. In this review, we discuss therapeutic strategies which utilize various combinations of protease inhibitors, NS5A inhibitors, nucleotide polymerase inhibitors and non-nucleoside polymerase inhibitors along with pegylated interferon in the treatment of chronic HCV.

• References

• 1 Jacobson IM, McHutchison JG, Dusheiko G , et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25) 2405-2416
  CrossrefPubMedGoogle Scholar
• 2 Poordad F, McCone Jr J, Bacon BR , et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13) 1195-1206
  CrossrefPubMedGoogle Scholar
• 3 Di Bisceglie A, Kuo A, Rustgi V, Sulkowski M. Virological outcomes and adherence to treatment algorithms in a longitudinal study of patients with chronic hepatitis C treated with boceprevir or telaprevir in the U.S. (HCV-TARGET). Paper presented at: AASLD The Liver Meeting; November 1–5, 2013; Washington, DC
  PubMedGoogle Scholar
• 4 Brass V, Berke JM, Montserret R, Blum HE, Penin F, Moradpour D. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc Natl Acad Sci U S A 2008; 105 (38) 14545-14550
  CrossrefPubMedGoogle Scholar
• 5 Loo YM, Owen DM, Li K , et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A 2006; 103 (15) 6001-6006
  CrossrefPubMedGoogle Scholar
• 6 Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int 2013; 33 (Suppl. 01) 80-84
  CrossrefPubMedGoogle Scholar
• 7 Jacobson I, Dore G, Foster G, Fried M. Simeprevir (TMC435) with peginterferon/ribavirin for chronic hCV genotype 1 infection in treatment-naïve patients: results from QUEST-1, a Phase III trial. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands
  PubMedGoogle Scholar
• 8 Olysio. Available at: http:www:olysio.com . Accessed February 9, 2014
  PubMedGoogle Scholar
• 9 Manns M, Marcellin P, Poordad F, Addonso de Araujo E. Simeprevir (TMC435) with peginterferon-α2a or -α2b and ribavirin in treatment-naïve HCV genotype 1 patients: QUEST-2, a randomised phase III trial. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands
  PubMedGoogle Scholar
• 10 Zeuzem S, Berg T, Gane E , et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a Phase IIb trial. Gastroenterology 2014; 146 (2) 430-, e6
  CrossrefPubMedGoogle Scholar
• 11 Summa V, Ludmerer SW, McCauley JA , et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012; 56 (8) 4161-4167
  CrossrefPubMedGoogle Scholar
• 12 Manns M, Vierling J, Bacon B, Marcellin P. High sustained viral response of MK-5172 with pegylated interferon alfa-2b and ribavirin in HCV genotype 1 treatment-naive non-cirrhotic patients. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands
  PubMedGoogle Scholar
• 13 Bronowicki JP, Pol S, Thuluvath PJ , et al. Randomized study of asunaprevir plus pegylated interferon-. α and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir Ther 2013; 18 (7) 885-893
  CrossrefPubMedGoogle Scholar
• 14 Bronowicki JP, Ratziu V, Gadano A, Thuluvath PJ. Asunaprevir with peginterferon-alfa and ribavirin in treatment-naive patients with genotype-1 or -4 chronic hepatitis C: SVR24 results from a randomized phase 2b study (AI447–016). Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands
  PubMedGoogle Scholar
• 15 Sulkowski MS, Asselah T, Lalezari J , et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 2013; 57 (6) 2143-2154
  CrossrefPubMedGoogle Scholar
• 16 Sulkowski MS, Bourlière M, Bronowicki JP , et al. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013; 57 (6) 2155-2163
  CrossrefPubMedGoogle Scholar
• 17 Jensen D, Asselah TD . D., Foster GR. A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic hepatitis C genotype-1 infection. Paper presented at: AASLD The Liver Meeting; November 1–5, 2013; Washington, DC
  PubMedGoogle Scholar
• 18 Jacobson I, Asselah T, Ferenci P, Foster G. STARTVerso3: A randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection. Paper presented at: AASLD The Liver Meeting; November 1–5, 2013; Washington, DC
  PubMedGoogle Scholar
• 19 Rockstroh J, Nelson M, Soriano V, Arasteh K. STARTVerso 4 Phase III trial of faldaprevir plus peg interferon alfa-2a and ribavirin (PR) in patients with HIV and HCV genotype 1 coinfection: end of treatment response. Paper presented at: AASLD The Liver Meeting; November 1–5, 2013; Washington, DC
  PubMedGoogle Scholar
• 20 Lee C. Daclatasvir: potential role in hepatitis C. Drug Des Devel Ther 2013; 7: 1223-1233
  PubMedGoogle Scholar
• 21 Gao M, Nettles RE, Belema M , et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465 (7294) 96-100
  CrossrefPubMedGoogle Scholar
• 22 Dore G, Lawitz E, Hezode C, Shafran SD. Daclatasvir combined with Peginterferon Alfa 2a Alfa-and Ribavirin for 12 or 16 Weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT 2/3 study. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands
  PubMedGoogle Scholar
• 23 Hezode C, Hirschfield GM, Ghesquiere W, Sievert W. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 patients: phase 2b COMMAND-1 SVR12 results. Paper presented at: AASLD The Liver Meeting; November 9–13, 2012; Boston, MA
  PubMedGoogle Scholar
• 24 Au JS, Pockros PJ. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther 2013; 95 (1) 78-88
  CrossrefPubMedGoogle Scholar
• 25 Lawitz E, Rodriquez-Torres M, Rustgi V, Hassanein T. Safety and antiviral activity of ANA598 in combination with pegylated interferon α2a plus ribavirin in treatment-naïve genotype-1 chronic HCV patients. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands
  PubMedGoogle Scholar
• 26 Available at: A study of setrobuvir in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in patients with genotype 1 chronic hepatitis C. Available at: www.clinicaltrials.gov . Accessed December 27, 2013
  PubMed
• 27 Zeuzem S, Soriano V, Asselah T , et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369 (7) 630-639
  CrossrefPubMedGoogle Scholar
• 28 Larrey D, Lohse AW, de Ledinghen V , et al. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol 2012; 57 (1) 39-46
  CrossrefPubMedGoogle Scholar
• 29 Kowdley KV, Lawitz E, Crespo I , et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381 (9883) 2100-2107
  CrossrefPubMedGoogle Scholar
• 30 Lawitz E, Lalezari JP, Hassanein T , et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13 (5) 401-408
  CrossrefPubMedGoogle Scholar
• 31 Lawitz E, Mangia A, Wyles D , et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368 (20) 1878-1887
  CrossrefPubMedGoogle Scholar
• 32 Wedemeyer H, Jensen D, Herring Jr R , et al; PROPEL Investigators. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. Hepatology 2013; 58 (2) 524-537
  CrossrefPubMedGoogle Scholar
• 33 Pockros PJ, Jensen D, Tsai N , et al; JUMP-C Investigators. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Hepatology 2013; 58 (2) 514-523
  CrossrefPubMedGoogle Scholar
• 34 Feld J, Jacobson I, Jensen D, Foster G. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine and ribavirin with or without peginterferon alfa-2a (40KD) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study. Paper presented at: AASLD The Liver Meeting; November 9–13, 2012; Boston, MA
  PubMedGoogle Scholar
• 35 ClinicalTrials.gov. A study of mericitabine in combination with telaprevir and Pegasys/Copegus in patients with chronic hepatitis C. Available at: http://clinicaltrials.gov/ct2/show/NCT01482390?term=mericitabine&rank=1 . Accessed February 9, 2014
  PubMedGoogle Scholar
• 36 ClinicalTrials.gov. A study of mericitabine in combination with boceprevir and Pegasys/Copegus in patients with chronic hepatitis C. Available at: http://clinicaltrials.gov/ct2/show/NCT01482403?term=mericitabine&rank=2 . Accessed February 9, 2014
  PubMedGoogle Scholar
• 37 Lok AS, Gardiner DF, Lawitz E , et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366 (3) 216-224
  CrossrefPubMedGoogle Scholar
• 38 Lok AS, Hezode C, Lawitz E, Gardiner DF. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 Inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV). Paper presented at: AASLD The Liver Meeting; November 9–13, 2012; Boston, MA
  PubMedGoogle Scholar
• 39 Gane E, Di Bisceglie A, Sulkowski M, Jacobson I. VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naïve genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 interim analysis. Paper presented at: The 22st Conference of the Asian Pacific Association for the Study of the Liver APASL February 16–19, 2012; Taipei, Taiwan
  PubMedGoogle Scholar
• 40 Zeuzem S, Buggisch P, Agarwal K , et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012; 55 (3) 749-758
  CrossrefPubMedGoogle Scholar
• 41 Pol S, Jablkowski M, Trenkle J, Kanwar B. Antiviral efficacy of the once daily NS3 protease inhibitor GS-9451, the non-nucleoside NS5B inhibitor tegobuvir (GS-9190), and pegylated interferon + ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection. Paper presented at: The 48th Annual Meeting of the European Association for Study of the Liver Amsterdam; April 24–28, 2013; Amsterdam, The Netherlands
  PubMedGoogle Scholar